EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Long‐term treatment with carbamazepine restores cognitive abilities in a mouse model of KCNQ2 developmental and epileptic encephalopathy

Jordane Louis, Natalia Doudka, Marie-Solenne Félix, Adeline Spiga Ghata, Camille Espanet, Romain Guilhaumou, Mathieu Milh iD, Laurent Villard iD

Epilepsia Open · 2025

DOI: 10.1002/epi4.70087 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Epilepsia Open, 2025. Verfasst von Jordane Louis und 7 weiteren Autor:innen. Beteiligte Einrichtung: Aix Marseille Univ, Inserm, MMG, U1251, Marseille, France. Hauptthemen laut MEDLINE: Carbamazepine, Anticonvulsants, KCNQ2 Potassium Channel, Cognition. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: European Joint Program on Rare Diseases, Agence Nationale de la Recherche.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Carbamazepine is the first line treatment for patients affected by KCNQ2 developmental and epileptic encephalopathy. It is efficient to reduce or stop seizures in this context. However, its effect on the neurodevelopmental outcomes is debated. The aim of this study was to evaluate the efficacy of long‐term oral administration of carbamazepine in a mouse model of Kcnq2 dysfunction.

Methods

Mice were treated at weaning and during 70 days. The impact on seizures was measured, and blood samples were collected every week. At 3 months of age, all mice were tested using the Water T‐maze and Barnes maze tests to evaluate their cognitive abilities. Brain tissue was collected to measure carbamazepine and carbamazepine‐epoxide concentrations.

Results

After 70 days of carbamazepine treatment, the impact on seizures was strong in the Kcnq2 ‐DEE mice, with 1 out of 12 treated knock‐in mice having a seizure compared to 8 out of 13 mice receiving the vehicle. Carbamazepine efficacy on seizures was progressive and correlated to an accumulation of carbamazepine‐epoxide in the brain. The cognitive abilities of treated knock‐in mice at 3 months of age were similar to those of wild‐type mice. Significance In addition to validating this knock‐in model as a model of anticonvulsant efficacy, these results reveal that carbamazepine‐epoxide accumulates in the brain when given over a long period of time. They also show that chronic treatment with carbamazepine strongly impacts cognitive abilities in a mouse model of Kcnq2 ‐DEE, questioning current treatment strategies in human patients. Plain Language Summary This study evaluated the long‐term effects of a treatment with an antiepileptic drug called carbamazepine (CBZ). It was performed in a mouse model of a severe form of genetic epilepsy. The results showed that a chronic treatment with CBZ effectively reduced seizures. Treated mice also showed improved cognitive abilities. An accumulation of a modified form of CBZ was measured in the brain of the treated animals. These findings call for a reevaluation of the long‐term effects of CBZ treatment in humans, as the animal data suggest potential beneficial effects that may not yet be fully appreciated in clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CarbamazepineAnticonvulsantsKCNQ2 Potassium ChannelCognitionEpilepsyAnimalsMiceDisease Models, AnimalMaleBrainMaze LearningMice, TransgenicSeizuresFemaleNerve Tissue Proteins

Stichwörter der Autor:innen

KCNQ2carbamazepinechronic treatmentcognitive deficitsdevelopmental and epileptic encephalopathy

Substanzen

CarbamazepineAnticonvulsantsKCNQ2 Potassium ChannelKcnq2 protein, mousecarbamazepine epoxideNerve Tissue Proteins

Autor:innen und Institutionen

  • Aix Marseille Univ, Inserm, MMG, U1251, Marseille, France.
  • Service de Pharmacologie Clinique et Pharmacosurveillance, AP-HM, Marseille, France.
  • Aix Marseille Univ, Inserm UMR 1106, INS, Marseille, France.
  • Service de Neurologie Pediatrique, AP-HM, Marseille, France.
  • Service de Génétique Médicale, AP-HM, Marseille, France.

ORCID-Profile: Mathieu Milh, Laurent Villard

Förderung

  • European Joint Program on Rare Diseases
  • Agence Nationale de la Recherche

Zitieren

APA

Louis, J., Doudka, N., Félix, M. S., Spiga Ghata, A., Espanet, C., Guilhaumou, R., Milh, M., & Villard, L. (2025). Long‐term treatment with carbamazepine restores cognitive abilities in a mouse model of KCNQ2 developmental and epileptic encephalopathy. Epilepsia Open. https://doi.org/10.1002/epi4.70087

Vancouver

Louis J, Doudka N, Félix MS, Spiga Ghata A, Espanet C, Guilhaumou R, et al. Long‐term treatment with carbamazepine restores cognitive abilities in a mouse model of KCNQ2 developmental and epileptic encephalopathy. Epilepsia Open. 2025. doi:10.1002/epi4.70087

BibTeX
@article{Louis2025,
  author = {Louis, Jordane and Doudka, Natalia and Félix, Marie-Solenne and Spiga Ghata, Adeline and Espanet, Camille and Guilhaumou, Romain and Milh, Mathieu and Villard, Laurent},
  title = {Long‐term treatment with carbamazepine restores cognitive abilities in a mouse model of KCNQ2 developmental and epileptic encephalopathy},
  journal = {Epilepsia Open},
  year = {2025},
  doi = {10.1002/epi4.70087}
}
Kostenlos starten →